The Life Sciences & Technology team of BGP Litigation has acted as legal counsel for Binnopharm Group in a major transaction for the acquisition of a portfolio of anti-bacterial medicines belonging to Dr Reddy’s brands Ciprolet and Levolet in Russia and the CIS. As a result of the deal, Binnopharm Group will reinforce its position as a leader in the antibiotics market in the respective territories, while Dr. Reddy’s will focus its strategic resources and capabilities in its key therapy areas.
The Firm’s lawyers supported the deal through all stages of transaction work and negotiations, ensuring superior drafting and dynamic development of the project, all of which allowed it to be implemented within a short time frame. By now, the transfer of rights to all marketing authorisations for the medicines acquired has been completed and the bulk of the deal can be deemed closed.
“We very much appreciate BGP Litigation’s support in this project. The team’s experience, profound expertise, and excellent understanding of our business needs allowed us to proceed with the negotiations most efficiently and to successfully close the deal,” Binnopharm Group’s representatives comment.